All News

2020

December

Media Release / Dec 14, 2020

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Read More

November

Media Release / Nov 06, 2020

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

Read More

October

Media Release / Oct 01, 2020

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

Read More

September

Media Release / Sep 23, 2020

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

Read More

July

Media Release / Jul 16, 2020

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Read More

May

Media Release / May 19, 2020

AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Read More

April

Media Release / Apr 28, 2020

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

Read More

March

Media Release / Mar 27, 2020

AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Read More
Media Release / Mar 24, 2020

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

Read More
Media Release / Mar 24, 2020

AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More